Literature DB >> 15625656

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

Arun J Sanyal1, Pouneh S Mofrad, Melissa J Contos, Carol Sargeant, Velimir A Luketic, Richard K Sterling, R Todd Stravitz, Mitchell L Shiffman, John Clore, Alan S Mills.   

Abstract

BACKGROUND & AIMS: Insulin resistance and oxidative stress contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). We conducted a pilot study for the following reasons: (1) to test the hypothesis that a combination of an antioxidant (vitamin E) and an insulin sensitizer (pioglitazone) would be superior to vitamin E alone for the treatment of NASH, and (2) to define the effects of these interventions on insulin-sensitive metabolic functions and correlate the effects with changes in liver histology.
METHODS: A randomized prospective trial was performed to compare the efficacy and safety of vitamin E alone (400 IU/day) vs. vitamin E (400 IU/day) and pioglitazone (30 mg/day) in nondiabetic, noncirrhotic subjects with NASH. Metabolic functions were assessed by a 2-step, hyperinsulinemic (10 and 40 mU/m2/min) euglycemic clamp.
RESULTS: A total of 10 patients were randomized to each arm. Two patients on combination therapy discontinued treatment; one because of pregnancy and the other because of hepatotoxicity. Treatment with vitamin E only produced a significant decrease in steatosis (mean grade, 2.2 vs. 1.4; P < .02). Compared with baseline, combination therapy produced a significant decrease in steatosis (mean, 2.3 vs. 1; P < .002), cytologic ballooning (1.3 vs. 0.2; P < .01), Mallory's hyaline (0.7 vs. 0.2; P < .04), and pericellular fibrosis (1.2 vs. 0.6; P < .03). Although vitamin E had no significant effects, combination therapy produced a significant increase in metabolic clearance of glucose and a decrease in fasting free fatty acid (FFA) and insulin. The decrease in fasting FFA and insulin independently predicted improvement in hepatic steatosis and cytologic ballooning.
CONCLUSIONS: A combination of vitamin E and pioglitazone produces a greater improvement in NASH histology. The improvement in steatosis and cytologic ballooning are related to treatment-associated decreases in fasting FFA and insulin levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15625656     DOI: 10.1016/s1542-3565(04)00457-4

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  126 in total

1.  Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.

Authors:  Samer Gawrieh; Miranda C Marion; Richard Komorowski; James Wallace; Michael Charlton; Ahmed Kissebah; Carl D Langefeld; Michael Olivier
Journal:  Dig Dis Sci       Date:  2011-12-09       Impact factor: 3.199

2.  Multifocal nodular nonalcoholic steatohepatitis: resolution with rosiglitazone.

Authors:  Charles Berkelhammer; Hugo Cuadros; Andrea Blumstein; George Mesleh; Manishkumar Patel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 3.  Quantification of liver fat with magnetic resonance imaging.

Authors:  Scott B Reeder; Claude B Sirlin
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

4.  Clinical trial report: treatment of nonalcoholic steatohepatitis with vitamin E.

Authors:  Bruce R Bacon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 5.  Role of vitamins in gastrointestinal diseases.

Authors:  Omar A Masri; Jean M Chalhoub; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

Review 6.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

7.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

8.  Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.

Authors:  Sridevi Devaraj; Rong Tang; Beverley Adams-Huet; Andrea Harris; Thanalakshmi Seenivasan; James A de Lemos; Ishwarlal Jialal
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

Review 9.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 10.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.